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The classic ketogenic diet (CKD) as a potential epilepsy treatment 
with high-fat has not good tolerability in some patients, and so many 
families refuse to use this diet for long term especially in children 
younger than 2 year. In the present study, the efficacy and tolerability 
of the CKD only diet were compared with CKD combined a formula-
based powder in children between 1 and 3 yr with intractable epilepsy. 
Materials & Methods
We randomly enrolled 45 children referred to Mofid Children’s 
Hospital, Tehran, Iran from April 2016 to May 2017 with refractory 
epilepsy for CKD only (control group), and formula based CKD 
(experimental group) treatment. Subjects were followed up for at 
least six months. 
Results
Most of the patients in CKD only group did not tolerate the diet and 
were reluctant to eat homemade foods with high fat. All families of 
the patients younger than 2 yr old in this group chose to discontinue 
CKD and pursued other options. About 33% of the families of the 
patients younger than 2 yr old and 41.6% of the total patients between 
1-3 yr old in experimental group stayed to the end of the trial, and all 
of them showed more than 90% reduction in seizure frequency after 
6 months. Moreover, regardless of the other variables, using formula 
increased the chance of responding to treatment 7.32 times. 
Conclusion
A ketogenic diet using a powder ketogenic formula is effective, safe, 
and tolerable in infants and children with refractory seizure especially 
for younger patients who are reluctant to eat ketogenic homemade 
foods. 
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Introduction
Epilepsy is the most common neurologic disorder 
in children and 20%-25% of these patients are 
resistant to medical treatments which impose high 
expenses on the family and affects their quality of 
life (1,2). Other treatment options such as surgery 
need to have a special epileptic focus. In addition, 
most of the refractory seizures have genetic origins 
without any brain epileptic focus, and the surgery 
option is available only in a small number of 
countries (1-4). 
Ketogenic diet has been a well-known treatment 
for refractory seizures since 1972 with positive 
effects on patients’ social and cognitive abilities (3, 
5-7). However, most of the studies about ketogenic 
diet have been designed for children over three 
years old or in a wide age range group without 
age categorization (8-12). Ketogenic formula 
powder is a commercial product that tastes similar 
to infantile formula. In the first days of starting 
ketogenic diet during which a child often refuses 
solid food, this formula is simply acceptable and is 
a suitable alternative (9). 
However, there are few studies about the efficacy 
of the respective diet in children especially children 
younger than 2 yr old. Therefore, we aimed to study 
and compare the tolerability and efficacy of classic 
ketogenic diet with the powder formula in children 
between 1 and 3 yr of age with intractable epilepsy. 
Materials & Methods
Overall, 45 children, 12-36 months with refractory 
seizure, referred to Pediatric Neurology Department 
of Mofid Children’s Hospital (Major tertiary 
university-affiliated Child Neurology Center in 
Tehran, Iran) from April 2016 to May 2017 were 
enrolled in our study. 
The parents were informed about all objectives and 
details of the research. The exclusion and inclusion 
criteria were evaluated completely for each patient, 
and the cases were evaluated by trained nutritionist 
and skilled staff. 
This research was evaluated and approved by 
the Ethical Board Committee of Shahid Beheshti 
University of Medical Science, Tehran, Iran (IR.
SBMU.REC.1396.1)
The inclusion criteria consisted of children 
between 11-36 months, with at least 2 episodes 
of refractory seizure per week, treated with three 
first-line antiepileptic medications for at least 
3 months before admission. They should also 
have compliant parents. The exclusion criteria 
comprised metabolic diseases such as fatty 
acid oxidation disorders and primary carnitine 
deficiency, dilated cardiomyopathy, systemic 
disorders diabetes mellitus, and organic acidemia 
disorders. At first, a complete history was taken 
and physical examination was done. 
Urine organic acids measurement, serum and 
urine amino acids chromatography, acylcarnitine 
profile, ammonia, lactate, pyruvate and mass 
spectrophotometric-based metabolic acid 
measurements were performed to rule out any 
metabolic diseases. Brain MRI was done for each 
patient, and EEG was performed before admission. 
Twenty-one cases entered the classic ketogenic 
diet group without KetoCal® (CKD only) and 24 
cases randomly entered the ketogenic KetoCal® 
formula group. As the primary step, after obtaining 
informed consent, children received 67 cc/kg water 
regimen. Electrolyte analysis, lipid profile, urine 
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ketone was assessed in every urination episode, 
and blood sugar was measured three times a day. 
After urine ketone reached the desired amount 
(+2 to +3), the ketogenic diet was started with the 
following order: First day, one third of 70% of 
calculated calorie for age and gender. Second day, 
two third of 70% of calculated calorie for age and 
gender. Third day, total calorie in three meals. In 
the KetoCal® group, the patients ranging from12- 
yr old and 2-3 yr old received KetoCal® formula 
providing 50% and 30% of calculated calorie, 
respectively. 
The patients were followed up for 6 months. 
Complete medical evaluation was done by an 
expert neurologist and nutritionist in the 1st, 3rd, 
and 6th months after admission. The parents were 
asked to record seizures frequency and report 
any complications. During the follow-up and 
interviews, if the seizure reduction was less than 
50% of the baseline after three months, and in case 
of irreversible lethargy, pancreatitis, triglyceride 
level more than 1000 mg/dl, and persistent 
urolithiasis, the diet would be stopped and the 
patient would be excluded from the study.
Statistical analysis was performed using SPSS 
Statistical Software (ver. 22, Chicago, IL, USA), 
and Stata Statistical Software (ver. 13). Student’s 
t-test, chi-square, Fisher exact test, Mann-Whitney, 
and McNemar test were used to compare the 
results. P-value less than 0.05 was considered as 
statistically significant. 
Results
All 45 cases admitted in the present study had 
neurological disabilities including different types 
of global developmental delays. 
The frequency of seizure, EEG changes, anti-
epileptic medications, and the neurodevelopmental 
condition were evaluated in both groups. The 
demographic factors, age, gender, weight, and 
head circumference between two groups had no 
significant differences (P>0.05). Both groups were 
similar in terms of MRI results, EEG, triglyceride 
and cholesterol (or LDL) level, and random urine 
Ca/Cr ratio. The age difference between two groups 
were not statistically significant. 
The mean±standard deviation of the follow-up 
duration was 0.671.8 months in CKD only group 
and 3.08±2.69 months in KetoCal® group. The 
follow-up duration difference between the two 
groups was significant (P<0.05). 
The frequency of weekly seizures was assessed 
in 1st, 3rd, and 6th month after intervention in both 
groups (Table 1). About 50% seizure reduction 
was more prominent in KetoCal® group than 
CKD only group, and the difference between the 
two groups was statistically significant (P<0.05). 
Seizure reduction between two groups was 
also compared based on the seizure type. In the 
KetoCal® group, the therapeutic response in the 3rd 
and 6th months of follow-up was quite remarkable 
in myoclonic seizures and infantile spasm, with a 
significant statistical difference (P<0.01) (Table 
2). The effect of age, gender, and type of seizure 
on the therapeutic response were studied. Based 
on the results (Table 3), the 50%-reduction of 
seizure was significantly higher in individuals who 
were in KetoCal® group than in CKD only group 
(Odds ratio: 7.32, Confidence Interval: 2.27-23.58, 
P<0.05). In addition, other variables such as seizure 
type and age showed a significant effect on seizure 
reduction. Success rate was higher in the children 
with myoclonic seizure type when compared with 
other types of seizure (Odds ratio: 1.49, Confidence 
Interval: 1.09-2.08, P<0.05). Furthermore, the 
more the age of the patient, the more the therapeutic 
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response (for each month increase in age, the 
therapeutic response was increased about 6%, with 
confidence limit of 1.005-1.11)
In the KetoCal® group at the time of admission, 1 out 
of 24 cases had normal EEG, while after 6 months of 
study, 6 out of 10 patients had normal EEG, and the 
difference was statistically significant (P<0.05). 
Since several cases were excluded from the CKD 
only diet group in the first month, we were not able 
to evaluate EEG in this group. 
At the time of admission, 21 out of 24 patients 
in the KetoCal® group had a moderate to severe 
cognitive developmental disorder based on Denver 
scoring, while after 6 months this ratio became 0.3, 
which was statistically significant (P<0.05).
 The excluded cases from the CKD group were 90.5 
%( 19 out of 21 cases) and in the KetoCal® group 
was 58.3% (14 out of 24 cases). The difference was 
statistically significant (P<0.05). After 6 months, 
100% (11 out of 11 patients) and 61.7% (8 out of 
13 patients) of the patients under 2 yr old were 
excluded from CKD only and KetoCal® groups, 
respectively, and the difference was statistically 
significant (P<0.05).
The complications observed in KetoCal® group 
included resistant urolithiasis in one patient 
and irreversible mental deterioration especially 
decreased cognition in two patients. All excluded 
cases from CKD only group between 1-2 yr old 
happened to be for the diet intolerability in the first 
week of admission. In KetoCal® group, 6 patients 
between the age of 2 to 3 yr were excluded from 
the study as one patient in the first week, 3 patients 
after one month, and 2 patients after three months. 
Seizure recurrence and/or diet intolerability were 
the main reasons for exclusion from the KetoCal® 
group. In CKD only group, 8 of 19 patients were 
excluded because of the lack of ketone production. 
However this was not seen in KetoCal® group. 
None of the patients were excluded from the study 
because of the lack of ketone production. None 
of the patients had biochemical disorders causing 
the ketogenic diet to be discontinued. The random 
urine Ca/Cr ration was more than 0.2 in 13 patients, 
treated with polycitrate-potassium.
Table 1. The number of patients who stayed in different groups in different months
 Ketogenic diet 1 month 3 month 6 month
Classic diet without ketocal® 4(19%) 2(9.5%) 2(9.5%)
Classic diet with ketocal® 18(75%) 13(54.2%) 10(41.7%)
P-value <0.001 0.002 0.02
Table 2. The number of patients that their seizures decreased to less than half after diet, based on the seizure type 
Time
Ketogenic Diet    Seizure Type 1 Month 3 Month  6 Month
Classic diet without 
Ketocal® 
Infantile spasm and 
myoclonus
2(16.7%) 1(8.3%) 1(8.3%)
Others 2(22.2) 1(11.1) 1(11.1)
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P-value 0.59 0.69 0.69
Classic Diet with Ketocal® 
Infantile spasm and 
myoclonus
12(58.7) 10(71.4) 9(64.3)
Others 6(60) 3(30) 1(10)
P-value 0.19 0.05 0.01
Table 3. The effect of age and sex in treatment response
Variable OR 15%CLOR P-value
Ketocal® diet 7.32 (2.27-23.58) 0.001
Seizure type :myoclonic 1.49 (1.09-2.08) 0.013
Sex 0.78 (0.27-2.28) 0.65
Age 1.06 (1.005-1.11) 0.04
Discussion 
CKD as a potential epilepsy treatment is a high-fat, 
low carbohydrate diet and is strongly considered 
in children who failed two or three antiepileptic 
drugs, regardless of the age (13-15). In addition, 
it is the diet of choice for the treatment of diseases 
such as pyruvate dehydrogenase deficiency and 
glucose transporter protein 1 (GLUT-1) deficiency 
syndrome (15-18). However, CKD as a high-fat 
diet has not good tolerability in some patients, and 
many families refuse to use the diet for the long 
term especially in children younger than 2 yr old. 
Many prospective studies that studied the effect of 
CKD in the treatment of epilepsy in long term have 
been performed in patients older than 2 yr old (19).
In the present study, the efficacy and tolerability 
of CKD only and formula-based CKD with 
KetoCal® 4 to 1 powder have been studied in 
children with intractable epilepsy. Most patients 
in CKD only group did not tolerate the diet and 
were reluctant to eat homemade food with high 
fat. All families of the patients younger than 2 yr 
old in this group chose to discontinue CKD and 
pursued other options. On the other hand, 33% of 
the families with patients younger than 2 yr old in 
KetoCal® group remained to the end of the trial. 
Although in comparison with CKD only group, 
more patients remained in KetoCal® group, a 
significant percentage of families in KetoCal® 
group also discontinued the diet. At the beginning 
of the study, the children fasted in the hospital 
for 72 h, and it was probably one of the major 
causes of family dissatisfaction. Therefore, the 
authors suggested removing the fasting period or 
shortening it. In this case, 3:1 diet can be used to 
gradually increase blood ketone levels and  obtain 
appropriate ketonuria. Our results indicate that 
ketogenic diet using the powder formula such as 
KetoCal® was palatable and tolerable and can be 
a suitable diet especially for infants and children 
who are reluctant to eat homemade food. These 
results are in line with the results of a previous 
study that showed the efficacy and tolerability of 
KetoCal® in children with refractory seizures (8). 
Overall, the diet of 59% of parents was palatable 
and tolerable enough. In the present study, the 
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response rate to the ketogenic diet was age-related 
as with increasing every month of age the response 
rate to treatment increased by 6%. However, 
ketogenic diet was more effective in younger 
patients. The researchers believe that production 
and utilization of ketone bodies in younger patients 
are better than older patients (20, 21). On the other 
hand, the response rate to the ketogenic diet was 
not age-related (10). We found that in the younger 
patients, not only the tolerability of the ketogenic 
diet was poor, but also the efficacy of the diet was 
low. Compared to older patients, the increase of 
ketone bodies was not desirable in younger patients 
on ketogenic diet, and in case of boosting ketone 
bodies, the seizures were not well controlled. In 
older patients, the efficacy and tolerability of the 
ketogenic diet were better. 
The duration of follow-up had a statistically 
significant difference (P<0.05) between CKD only 
group (0.67 months) and KetoCal® group (3.08 
month), and most patients in CKD only group 
did not tolerate the diet and discontinued the trial. 
The percentage of patients who had a greater than 
50%-reduction of seizures after 1-3 and 6 months 
was higher in KetoCal® group in comparison with 
CKD only group (P<0.05). Regardless of the other 
variables, the KetoCal® diet increased the chance 
of responding to treatment 7.32 times. The efficacy 
and suitable tolerability of the ketogenic diet were 
showed in 38 infants and children between 3 months 
and 5 yr old with epileptic encephalopathies using 
ketogenic diet as KetoCal® formula alone or 80% 
of the daily caloric amount (10). All the children 
initiating the diet continued the diet for 1 month, and 
92%, 73.7%, and 52.7% of them continued the diet 
for at 3 months, 6 months and 1 year, respectively. 
They indicated that 28.9 % of children had a greater-
than-50%-reduction of seizures and 23.7% were 
seizure-free during a 12-months follow-up period. 
In a research study, one-third of the patients on the 
ketogenic diet showed more than 90% reduction in 
seizure. However, completely seizure-free subjects 
were rare (22). In another study, KetoCal® was 
used for children between 12 months and 5 yr old 
with refractory epilepsy who were reluctant to eat 
homemade food (8). During a 4-month follow-up 
the median seizure frequency per week was reduced 
in 68.2% of patients, 40.9% showed a 50%-90% 
reduction in seizure frequency per week, and 
27.3% showed more than 90% reduction in seizure 
frequency per week. Myoclonic seizure was a good 
prognostic factor as the patients with myoclonic 
seizure reacted favorably to the diet in comparison 
to other patients. The response rate to diet in the 
patients with infantile spasms, myoclonic, atonic, 
and tonic-clonic generalized seizures was better in 
comparison to complex partial seizures (23). 
In conclusion, a ketogenic diet using a powder 
formula (KetoCal®) is effective, safe, and tolerable 
in infants and children with refractory seizures. 
Response rate to ketogenic diet is age-related. 
The KetoCal® diet can be an appropriate choice 
especially for those younger than 2 yr old and 
patients who are reluctant to eat homemade food. 
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